Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
[en] The authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused.
Disciplines :
Oncology
Author, co-author :
Slamon, D J; David Geffen School of Medicine at UCLA, Los Angeles, USA. Electronic address: dslamon@mednet.ucla.edu
Neven, P; Multidisciplinary Breast Centre, Universitair Ziekenhuis Leuven, Leuven, Belgium
Chia, S; British Columbia Cancer Agency, Vancouver, Canada
Jerusalem, Guy ; Centre Hospitalier Universitaire de Liège - CHU > > Service d'oncologie médicale
De Laurentiis, M; Istituto Nazionale Tumori IRCCS 'Fondazione G. Pascale', Naples, Italy
Im, S; Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea
Petrakova, K; Masaryk Memorial Cancer Institute, Brno, Czech Republic
Valeria Bianchi, G; Fondazione Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale dei Tumori, Milan, Italy
Martín, M; Instituto de Investigación Sanitaria Gregorio Marañon, Centro de Investigación Biomédica en Red de Cáncer, Grupo Español de Investigación en Cáncer de Mama, Universidad Complutense, Madrid, Spain
Nusch, A; Practice for Hematology and Internal Oncology, Velbert, Germany
Sonke, G S; Netherlands Cancer Institute/Borstkanker Onderzoek Groep Study Center, Amsterdam, The Netherlands
De la Cruz-Merino, L; Hospital Universitario Virgen Macarena, Seville, Spain
Beck, J T; Highlands Oncology Group, Fayetteville, USA
Ji, Y; Novartis Pharmaceuticals Corporation, East Hanover, USA
Wang, C; Novartis Pharma AG, Basel, Switzerland
Deore, U; Novartis Pharmaceuticals Corporation, East Hanover, USA
Chakravartty, A; Novartis Pharmaceuticals Corporation, East Hanover, USA
Zarate, J P; Novartis Pharmaceuticals Corporation, East Hanover, USA
Taran, T; Novartis Pharma AG, Basel, Switzerland
Fasching, P A; Department of Gynecology and Obstetrics, University Hospital Erlangen, Comprehensive Cancer Center Erlangen-EMN, Friedrich-Alexander University Erlangen, Erlangen, Germany
Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].
Alternative titles :
[en] Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)
